Antibodies are essential tools in modern medicine and research, but not all antibodies are the same. VHH antibodies, also known as single-domain antibodies or nanobodies, are a type of antibody that offers several advantages over conventional antibodies.
VHH antibodies are derived from the immune system of camelids, which produce antibodies that are much smaller than those produced by humans or mice. VHH antibodies consist of a single domain, or variable region, that is capable of binding to specific antigens. This makes them ideal for a wide range of applications, including diagnostic tests, therapeutics, and research tools.
One key advantage of VHH antibodies is their small size. This allows them to penetrate tissues more effectively than larger antibodies, making them useful for targeting diseases that are difficult to reach with conventional therapies. Additionally, VHH antibodies are highly stable and can withstand harsh conditions, such as high temperatures or acidic environments, which makes them useful for a range of diagnostic and therapeutic applications.
At Biointron, we specialize in the production of high-quality recombinant VHH antibodies for research and diagnostic purposes. Our team of experts uses state-of-the-art technologies to generate VHH antibodies that are highly specific and sensitive to their target antigens. Whether you need custom VHH antibody production or off-the-shelf options, we have the expertise to deliver the right solution for your needs.
To learn more about our VHH antibody services, visit our website or contact us today.
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.